Research
Hormonal
Activation of the AMPK pathway inhibits hepatic glucose production, thereby lowering blood glucose levels in type 2 diabetes.
AMPK activation helps lower blood sugar by stopping the liver from producing too much glucose.
GoodSupportsHIGH confidence
It has been first shown that systemic infusion of AICAR in normal and insulin-resistant obese rats led to the inhibition of hepatic glucose production (HGP).
Why this rating
Supported by multiple in vivo and in vitro studies cited in the paper.
Source
Targeting the AMPK pathway for the treatment of Type 2 diabetes
Benoı̂t Viollet · Frontiers in bioscience · 2009
DOI 10.2741/3460
narrative_reviewCited 278×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →